Home Newsfeeds B of A Securities Downgrades AZEK Co to Neutral

B of A Securities Downgrades AZEK Co to Neutral

B of A Securities analyst Rafe Jadrosich downgrades AZEK Co (NYSE:AZEK) from Buy to Neutral.

byBenzinga Newsdesk

January 30, 2023

1 minute read

B of A Securities analyst Rafe Jadrosich downgrades AZEK Co (NYSE:AZEK) from Buy to Neutral.

Regeneron Pharmaceuticals Announces Libtayo Receives Positive CHMP Opinion Recommending Approval To Treat Advanced Cervical Cancer

By Benzinga Newsdesk

October 14, 7:05 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for

REGN

Analyst Ratings

What Analysts Are Saying About Newpark Resources Stock

By Benzinga Insights

May 6, 3:01 PM

Analysts’ ratings for Newpark Resources (NYSE:NR) over the last quarter vary from bullish to bearish, as provided by…

Northland Capital Markets Maintains Market Perform on Lumentum Holdings, Lowers Price Target to $57

By Benzinga Newsdesk

February 10, 9:24 AM

Northland Capital Markets analyst Tim Savageaux maintains Lumentum Holdings (NASDAQ:LITE) with a Market Perform and lowers the price target from $65 to $57.

LITE

MasTec Sees Q1 EPS $0.57 Vs $(0.25) Est.; Q1 Revenue $2.4B Vs $2.56B Est

By Happy Mohamed

February 24, 1:18 AM

For the first quarter of 2023, the Company expects revenue of approximately $2.4 billion. First quarter 2023 GAAP net loss is expected to approximate $86 million, with GAAP diluted loss per share expected to approximate $1.12. First quarter 2023 adjusted EBITDA is expected to approximate $100 million or 4.2% of revenue, with adjus

MTZ

B of A Securities Downgrades AZEK Co to Neutral

Related Posts

Regeneron Pharmaceuticals Announces Libtayo Receives Positive CHMP Opinion Recommending Approval To Treat Advanced Cervical Cancer

What Analysts Are Saying About Newpark Resources Stock

Northland Capital Markets Maintains Market Perform on Lumentum Holdings, Lowers Price Target to $57

MasTec Sees Q1 EPS $0.57 Vs $(0.25) Est.; Q1 Revenue $2.4B Vs $2.56B Est